XENE
HealthcareXenon Pharmaceuticals Inc.
$41.79
$-2.70 (-6.07%)
Jan 5, 2026
Price History (1Y)
Analysis
Xenon Pharmaceuticals Inc. (XENE) operates within the healthcare sector and biotechnology industry. The company has a market capitalization of $3.23 billion and employs approximately 316 individuals. The company's financial health is characterized by significant losses. Xenon Pharmaceuticals reported net income of -$306,334,016 and EBITDA of -$338,182,016 over the trailing twelve months (TTM). Additionally, the company has negative profitability margins, with a gross margin of 0.0%, operating margin of -4543.7%, and profit margin of 0.0%. The company's returns on equity (ROE) and assets (ROA) are also negative, at -45.1% and -29.5%, respectively. Xenon Pharmaceuticals has a debt-to-equity ratio of 1.49 and a current ratio of 12.53, indicating relatively high debt levels compared to equity. The company's valuation is complex, with a forward P/E ratio of -9.15 and an EV/EBITDA ratio of -8.82. The price to book ratio is 5.76, while the price to sales ratio is significantly higher at 430.58.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Visit website →Key Statistics
- Market Cap
- $3.23B
- P/E Ratio
- N/A
- 52-Week High
- $46.60
- 52-Week Low
- $26.74
- Avg Volume
- 797.15K
- Beta
- 0.98
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- Canada
- Employees
- 316